Recent advances, including higher-dose shorter course [11–13] and ultra-short course primaquine [14], single dose tafenoquine as a new drug [15, 16], and novel quantitative G6PD Point-of-care (POC) testing devices [17], are changing the landscape of products available for national malaria programs (NMPs) to tackle vivax malaria, but they haven’t been incorporated into global or national guidelines yet. The gene discussed is G6PD; the disease is malaria.